SWOG clinical trial number
S0635

A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features

95% Accrual
Accrual
95%
Closed
Phase
95% Accrual
Accrual
95%
Abbreviated Title
Phase II OSI-774/Bevacizumab in St. IIIB and IV BAC and AdenoBAC
Activated
07/15/2007
Closed
08/15/2011
Participants
NCORP, Members, Medical Oncologists, Affiliates

Research committees

Lung Cancer

Treatment

Bevacizumab Erlotinib

Other Clinical Trials

S2414
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
0% Accrual
Accrual
0%
Open
Phase
CTIU2317
SWOG Clinical Trial Number